GSK-3β, a pivotal kinase in Alzheimer disease

Frontiers in Molecular Neuroscience

Volumn 7, Issue MAY, 2014, Pages

  Llorens Martín, María ^a,b   Jurado, Jerónimo ^a,b   Hernández, Félix ^a,b,c   Ávila, Jesús ^a,b  

^a CSIC   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Alzheimer disease; GSK 3 ; Kinase; Neurodegeneration; Tau proteins

Indexed keywords

AMYLOID BETA PROTEIN; BETA CATENIN; BETA SECRETASE; GLYCOGEN SYNTHASE KINASE 3BETA; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; MICROTUBULE ASSOCIATED PROTEIN; SOMATOMEDIN C; TAU PROTEIN; TUMOR NECROSIS FACTOR;

ALZHEIMER DISEASE; APOPTOSIS; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; DISEASE COURSE; HUMAN; INFLAMMATION; MICROTUBULE; NERVE FIBER TRANSPORT; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION;

EID: 84901417472     PISSN: 16625099     EISSN: None     Source Type: Journal    
DOI: 10.3389/fnmol.2014.00046     Document Type: Review

References (169)

1. Alvarez, A. R., Godoy, J. A., Mullendorff, K., Olivares, G. H., Bronfman, M., and Ine-strosa, N. C. (2004).Wnt-3aovercomes beta-amyloidtoxicityin rathippocampal neurons. Exp. Cell Res. 297, 186-196. doi: 10.1016/j.yexcr.2004.02.028
2. Alzheimer's Association. (2012). 2012 Alzheimer's disease facts and figures. Alzheimers Dement. 8, 131-168. doi: 10.1016/j.jalz.2012.02.001
3. Arendt, T. (2003). Synaptic plasticity and cell cycle activation in neurons are alter-native effector pathways: the 'Dr. Jekyll and Mr. Hyde concept' of Alzheimer's disease or the yin and yang of neuroplasticity. Prog. Neurobiol. 71, 83-248. doi: 10.1016/j.pneurobio.2003.09.007
4. Arendt, T. (2009). Synaptic degeneration in Alzheimer's disease. Acta Neuropathol. 118, 167-179. doi: 10.1007/s00401-009-0536-x
5. Arendt, T., Rodel, L., Gartner, U., and Holzer, M. (1996). Expression of the cyclin-dependent kinase inhibitor p16 in Alzheimer's disease. Neuroreport 7, 3047-3049. doi: 10.1097/00001756-199611250-00050
6. Augustinack, J. C., Schneider, A., Mandelkow, E. M., and Hyman, B. T. (2002). Spe-cific tau phosphorylation sites correlate with severity of neuronal cytopathology inAlzheimer'sdisease. ActaNeuropathol. 103, 26-35. doi: 10.1007/s004010100423
7. Avrahami, L., Farfara, D., Shaham-Kol, M., Vassar, R., Frenkel, D., and Eldar-Finkelman, H. (2013). Inhibition of glycogen synthase kinase-3 ameliorates beta-amyloid pathologyand restores lysosomal acidification and mammalian target of rapamycin activity in the Alzheimer disease mouse model: in vivo and in vitro studies. J. Biol. Chem. 288, 1295-1306. doi: 10.1074/jbc.M112.409250
8. Bartzokis, G., Cummings, J. L., Sultzer, D., Henderson, V. W., Nuechterlein, K. H., and Mintz, J. (2003). White matter structural integrity in healthy aging adults and patients with Alzheimer disease: a magnetic resonance imaging study. Arch. Neurol. 60, 393-398. doi: 10.1001/archneur.60.3.393
9. Bastrikova, N., Gardner, G. A., Reece, J. M., Jeromin, A., and Dudek, S. M. (2008). Synapse elimination accompanies functional plasticity in hippocampal neurons. Proc. Natl. Acad. Sci. U.S.A. 105, 3123-3127. doi: 10.1073/pnas.0800027105
10. Beurel, E., and Jope, R. S. (2006). The paradoxical pro-and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways. Prog. Neurobiol. 79, 173-189. doi: 10.1016/j.pneurobio.2006.07.006
11. Bhat, R., Xue, Y., Berg, S., Hellberg, S., Ormo, M., Nilsson, Y., et al. (2003). Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J. Biol. Chem. 278, 45937-45945. doi: 10.1074/jbc.M306268200
12. Bhatt, D. H., Zhang, S., and Gan, W. B. (2009). Dendritic spine dynam-ics. Annu. Rev. Physiol. 71, 261-282. doi: 10.1146/annurev.physiol.010908. 163140
13. Bijur, G. N., De Sarno, P., and Jope, R. S. (2000). Glycogen synthase kinase-3beta facilitates staurosporine-and heat shock-induced apoptosis. Protection bylithium. J. Biol. Chem. 275, 7583-7590. doi: 10.1074/jbc.275.11.7583
14. Billingsley, M. L., and Kincaid, R. L. (1997). Regulatedphosphorylationand dephos-phorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration. Biochem. J. 323(Pt 3), 577-591.
15. Bischofberger, J. (2007). Young and excitable: new neurons in memory networks. Nat. Neurosci. 10, 273-275. doi: 10.1038/nn0307-273
16. Blennow, K., de Leon, M. J., and Zetterberg, H. (2006). Alzheimer's disease. Lancet 368, 387-403. doi: 10.1016/S0140-6736(06)69113-7
17. Bradley, C. A., Peineau, S., Taghibiglou, C., Nicolas, C. S., Whitcomb, D. J., Bor-tolotto, Z. A., et al. (2012). A pivotal role of GSK-3 in synaptic plasticity. Front. Mol. Neurosci. 5:13. doi: 10.3389/fnmol.2012.00013
18. Bretteville, A., and Planel, E. (2008). Tau aggregates: toxic, inert, or protective species? J.Alzheimers Dis. 14, 431-436.
19. Buxbaum, J. D., Thinakaran, G., Koliatsos, V., O'Callahan, J., Slunt, H. H., Price, D. L., et al. (1998). Alzheimer amyloid protein precursor in the rat hippocampus: transport and processing through the perforant path. J. Neurosci. 18, 9629-9637.
20. Caccamo, A., Oddo, S., Tran, L. X., and LaFerla, F. M. (2007). Lithium reduces tau phosphorylation but not A beta or working memory deficits in a trans-genic model with both plaques and tangles. Am. J. Pathol. 170, 1669-1675. doi: 10.2353/ajpath.2007.061178
21. Cai, H., Wang, Y., McCarthy, D., Wen, H., Borchelt, D. R., Price, D. L., et al. (2001). BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. Nat. Neurosci. 4, 233-234. doi: 10.1038/85064
22. Cai, Z., Zhao, Y., and Zhao, B. (2012). Roles of glycogen synthase kinase 3 in Alzheimer's disease. Curr. Alzheimer Res. 9, 864-879. doi: 10.2174/156720512802455386
23. Coghlan, M. P., Culbert, A. A., Cross, D. A., Corcoran, S. L., Yates, J. W., Pearce, N. J., et al. (2000). Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem. Biol. 7, 793-803. doi: 10.1016/S1074-5521(00)00025-9
24. Coleman, P. D., and Yao, P. J. (2003). Synaptic slaughter in Alzheimer's disease. Neurobiol.Aging 24, 1023-1027. doi: 10.1016/j.neurobiolaging.2003.09.001
25. Cross, D.A., Alessi, D. R., Cohen, P., Andjelkovich, M., andHemmings, B.A. (1995). Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378, 785-789. doi: 10.1038/378785a0
26. Christian, S. L., Sims, P. V., and Gold, M. R. (2002). The B cell antigen receptor reg-ulates the transcriptional activator beta-catenin via protein kinase C-mediated inhibition of glycogen synthase kinase-3. J. Immunol. 169, 758-769. doi: 10.4049/jimmunol.169.2.758
27. Chun, J., Kwon, T., Lee, E. J., Kim, C. H., Han, Y. S., Hong, S. K., et al. 14-3-3 Protein mediates phosphorylation of microtubule-associated pro-tein tau by serum-and glucocorticoid-induced protein kinase 1. Mol. Cells 18, 360-368.
28. Cullen, W. K., Suh, Y. H., Anwyl, R., and Rowan, M. J. (1997). Block of LTP in rat hippocampus in vivo by beta-amyloid precursor protein fragments. Neuroreport 8, 3213-3217. doi: 10.1097/00001756-199710200-00006
29. De Ferrari, G. V., Chacon, M. A., Barria, M. I., Garrido, J. L., Godoy, J. A., Olivares, G., et al. (2003). Activation of Wnt signaling rescues neurodegeneration and behavioral impairments induced by beta-amyloid fibrils. Mol. Psychiatry 8, 195-208. doi: 10.1038/sj.mp.4001208
30. delSer, T., Steinwachs, K. C., Gertz, H. J., Andres, M.V., Gomez-Carrillo, B., Medina, M., et al. (2013). Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: a pilot study. J. Alzheimers Dis. 33, 205-215. doi: 10.3233/JAD-2012-120805
31. Deng, Y., Xiong, Z., Chen, P., Wei, J., Chen, S. S., and Yan, Z. (2014). beta-amyloid impairs the regulation of N-methyl-D-aspartate recep-tors by glycogen synthase kinase 3. Neurobiol. Aging 35, 449-459. doi: 10.1016/j.neurobiolaging.2013.08.031
32. Dewachter, I., Ris, L., Jaworski, T., Seymour, C. M., Kremer, A., Borghgraef, P., et al. (2009). GSK3beta, a centre-staged kinase in neuropsychiatric disorders, modu-lates long term memory by inhibitory phosphorylation at serine-9. Neurobiol. Dis. 35, 193-200. doi: 10.1016/j.nbd.2009.04.003
33. Dickson, D. W., Ksiezak-Reding, H., Liu, W. K., Davies, P., Crowe, A., andYen, S. H. (1992). Immunocytochemistry of neurofibrillary tangles with antibodies to sub-regions of tau protein: identification of hidden and cleaved tau epitopes and a new phosphorylation site. Acta Neuropathol. 84, 596-605. doi: 10.1007/BF00227736
34. Ding, Y., Qiao, A., and Fan, G. H. (2010). Indirubin-3;-monoxime rescues spa-tial memory deficits and attenuates beta-amyloid-associated neuropathology in a mouse model of Alzheimer's disease. Neurobiol. Dis. 39, 156-168. doi: 10.1016/j.nbd.2010.03.022
35. Doble, B. W., and Woodgett, J. R. (2007). Role of glycogen synthase kinase-3 in cell fate and epithelial-mesenchymal transitions. Cells Tissues Organs 185, 73-84. doi: 10.1159/000101306
36. Du, J., Wei, Y., Liu, L., Wang, Y., Khairova, R., Blumenthal, R., et al. (2010). A kinesin signaling complex mediates the ability of GSK-3beta to affect mood-associated behaviors. Proc. Natl. Acad. Sci. U.S.A. 107, 11573-11578. doi: 10.1073/pnas.0913138107
37. Egashira, Y., Tanaka, T., Soni, P., Sakuragi, S., Tominaga-Yoshino, K., and Ogura, A. (2010). Involvement of the p75(NTR) signaling pathway in persistent synap-tic suppression coupled with synapse elimination following repeated long-term depression induction. J. Neurosci. Res. 88, 3433-3446. doi: 10.1002/jnr.22505
38. Embi, N., Rylatt, D. B., and Cohen, P. (1980). Glycogen synthase kinase-3 from rabbit skelet al muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur. J. Biochem. 107, 519-527. doi: 10.1111/j.1432-1033.1980.tb06059.x
39. Engel, T., Hernandez, F., Avila, J., and Lucas, J. J. (2006). Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional over-expression of glycogen synthase kinase-3. J. Neurosci. 26, 5083-5090. doi: 10.1523/JNEUROSCI.0604-06.2006
40. Fang, X., Yu, S. X., Lu, Y., Bast, R. C., Woodgett, J. R. Jr., and Mills, G. B. (2000). Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc. Natl. Acad. Sci. U.S.A. 97, 11960-11965. doi: 10.1073/pnas.220413597
41. Ferrari, A., Hoerndli, F., Baechi, T., Nitsch, R. M., and Gotz, J. (2003). beta-Amyloid induces paired helical filament-like tau filaments in tissue culture. J. Biol. Chem. 278, 40162-40168. doi: 10.1074/jbc.M308243200
42. Fiorentini, A., Rosi, M. C., Grossi, C., Luccarini, I., and Casamenti, F. (2010). Lithium improves hippocampal neurogenesis, neuropathology and cognitive functions in APP mutant mice. PLoS ONE 5:e14382. doi: 10.1371/jour-nal.pone.0014382
43. Forde, J. E., and Dale, T. C. (2007). Glycogen synthase kinase 3: a key regulator of cellularfate. Cell. Mol. LifeSci. 64, 1930-1944. doi: 10.1007/s00018-007-7045-7
44. Forlenza, O. V., de Paula, V. J., Machado-Vieira, R., Diniz, B. S., and Gattaz, W. F. (2012). Does lithium preventAlzheimer's disease? DrugsAging 29, 335-342. doi: 10.2165/11599180-000000000-00000
45. Forlenza, O. V., Diniz, B. S., Radanovic, M., Santos, F. S., Talib, L. L., and Gattaz, W. F. (2011). Disease-modifying properties of long-term lithium treatment for amnestic mildcognitiveimpairment:randomisedcontrolledtrial. Br. J. Psychiatry 198, 351-356. doi: 10.1192/bjp.bp.110.080044
46. Fukumoto, S., Hsieh, C. M., Maemura, K., Layne, M. D., Yet, S. F., Lee, K. H., et al. (2001). Akt participation in the Wnt signaling pathway through Dishevelled. J. Biol. Chem. 276, 17479-17483. doi: 10.1074/jbc.C000880200
47. Fuster-Matanzo, A., Llorens-Martin, M., de Barreda, E. G., Avila, J., and Hernandez, F. (2011). Different susceptibilityto neurodegeneration of dorsal andventral hip-pocampal dentate gyrus: a study with transgenic mice overexpressing GSK3beta. PLoS ONE 6:e27262. doi: 10.1371/journal.pone.0027262
48. Fuster-Matanzo, A., Llorens-Martin, M., Jurado-Arjona, J., Avila, J., and Hernandez, F. (2012). Tau protein and adult hippocampal neurogenesis. Front. Neurosci. 6:104. doi: 10.3389/fnins.2012.00104
49. Fuster-Matanzo, A., Llorens-Martin, M., Sirerol-Piquer, M. S., Garcia-Verdugo, J. M., Avila J., and Hernandez, F. (2013). Dual effects of increased glycogen synthase kinase-3beta activity on adult neurogenesis. Hum. Mol. Genet. 22, 1300-1315. doi: 10.1093/hmg/dds533
50. Ghosal, K., Vogt, D. L., Liang, M., Shen, Y., Lamb, B. T., and Pimplikar, S. W. (2009). Alzheimer's disease-like pathological features in transgenic mice expressing the APP intracellular domain. Proc. Natl. Acad. Sci. U.S.A. 106, 18367-18372. doi: 10.1073/pnas.0907652106
51. Godemann, R., Biernat, J., Mandelkow, E., and Mandelkow, E. M. (1999). Phospho-rylation of tau protein by recombinant GSK-3beta: pronounced phosphorylation at select Ser/Thr-Pro motifs but no phosphorylation at Ser262 in the repeat domain. FEBSLett. 454, 157-164. doi: 10.1016/S0014-5793(99)00741-3
52. Gomez de Barreda, E., Perez, M., Gomez Ramos, P., de Cristobal, J., Martin-Maestro, P., Moran, A., et al. (2010). Tau-knockout mice show reduced GSK3-induced hippocampal degeneration and learning deficits. Neurobiol. Dis. 37, 622-629. doi: 10.1016/j.nbd.2009.11.017
53. Gomez-Sintes, R., Hernandez, F., Bortolozzi, A., Artigas, F., Avila, J. J., Zaratin, P., et al. (2007). Neuronal apoptosis and reversible motor deficit in dominant-negative GSK-3 conditional transgenic mice. EMBO J. 26, 2743-2754. doi: 10.1038/sj.emboj.7601725
54. Gomez-Sintes, R., Hernandez, F., Lucas, J. J., and Avila, J. (2011). GSK-3 mouse models to studyneuronal apoptosis and neurodegeneration. Front. Mol. Neurosci. 4:45. doi: 10.3389/fnmol.2011.00045
55. Goni-Oliver, P., Avila, J., and Hernandez, F. (2009). Calpain-mediated truncation of GSK-3 in post-mortem brain samples. J. Neurosci. Res. 87, 1156-1161. doi: 10.1002/jnr.21932
56. Goni-Oliver, P., Lucas, J. J., Avila, J., and Hernandez, F. (2007). N-terminal cleavage of GSK-3 bycalpain: anewform of GSK-3 regulation. J. Biol. Chem. 282, 22406-22413. doi: 10.1074/jbc.M702793200
57. Gotz, J., Probst, A., Spillantini, M. G., Schafer, T., Jakes, R., Burki, K., et al. Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform. EMBO J. 14, 1304-1313.
58. Hanger, D. P., Byers, H. L., Wray, S., Leung, K. Y., Saxton, M. J., Seereeram, A., et al. H. Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis. J. Biol. Chem. 282, 23645-23654. doi: 10.1074/jbc.M703269200
59. Hashiguchi, M., and Hashiguchi, T. (2013). Kinase-kinase interaction and mod-ulation of tau phosphorylation. Int. Rev. Cell Mol. Biol. 300, 121-160. doi: 10.1016/B978-0-12-405210-9.00004-7
60. Hebert, L. E., Beckett, L.A., Scherr, P.A., and Evans, D.A. (2001).Annual incidence of Alzheimer disease in the United States projected to theyears 2000 through 2050. AlzheimerDis. Assoc. Disord. 15, 169-173. doi: 10.1097/00002093-200110000-00002
61. Hernandez, F., Borrell, J., Guaza, C., Avila, J., and Lucas, J. J. (2002). Spatial learning deficit in transgenic mice that conditionally over-express GSK-3beta in the brain but do not form tau filaments. J. Neurochem. 83, 1529-1533. doi: 10.1046/j.1471-4159.2002.01269.x
62. Holsinger, R. M., McLean, C. A., Beyreuther, K., Masters, C. L., and Evin, G. (2002). Increased expression of the amyloid precursor beta-secretase in Alzheimer's disease. Ann. Neurol. 51, 783-786. doi: 10.1002/ana.10208
63. Hooper, C., Markevich, V., Plattner, F., Killick, R., Schofield, E., Engel, T., et al. (2007). Glycogen synthase kinase-3 inhibition is integral to long-term potentiation. Eur. J. Neurosci. 25, 81-86. doi: 10.1111/j.1460-9568.2006.05245.x
64. Hoshi, M., Takashima, A., Noguchi, K., Murayama, M., Sato, M., Kondo, S., et al. Regulation of mitochondrial pyruvate dehydrogenase activitybytau pro-tein kinase I/glycogen synthase kinase 3beta in brain. Proc. Natl. Acad. Sci. U.S.A. 93, 2719-2723. doi: 10.1073/pnas.93.7.2719
65. Hurtado, D. E., Molina-Porcel, L., Carroll, J. C., Macdonald, C., Aboagye, A. K., Trojanowski, J. Q., et al. (2012). Selectively silencing GSK-3 isoforms reduces plaques and tangles in mouse models of Alzheimer's disease. J. Neurosci. 32, 7392-7402. doi: 10.1523/JNEUR0SCI.0889-12.2012
66. Illenberger, S., Zheng-Fischhofer, Q., Preuss, U., Stamer, K., Baumann, K., Trinczek, B., et al. (1998). The endogenous and cell cycle-dependent phosphorylation of tau protein in living cells: implications for Alzheimer's disease. Mol. Biol. Cell 9, 1495-1512. doi: 10.1091/mbc.9.6.1495
67. Isaac, J. T., Nicoll, R. A., and Malenka, R. C. (1995). Evidence for silent synapses: implications for the expression of LTP. Neuron 15, 427-434. doi: 10.1016/0896-6273(95)90046-2
68. Jimenez-Mateos, E. M., Gonzalez-Billault, C., Dawson, H. N., Vitek, M. P., and Avila, J. (2006). Role of MAP1B in axonal retrograde transport of mitochondria. Biochem. J. 397, 53-59. doi: 10.1042/BJ20060205
69. Johnson-Farley, N. N., Travkina, T., and Cowen, D. S. (2006). Cumulative activation of Akt and consequent inhibition of glycogen synthase kinase-3 by brain-derived neurotrophic factor and insulin-like growth factor-1 in cultured hippocam-pal neurons. J. Pharmacol. Exp. Ther. 316, 1062-1069. doi: 10.1124/jpet.105. 094433
70. Jope, R. S. (2003). Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes. Trends Pharmacol. Sci. 24, 441-443. doi: 10.1016/S0165-6147(03)00206-2
71. Jope, R. S. (2011). Glycogen synthase kinase-3 in the etiology and treatment of mood disorders. Front. Mol. Neurosci. 4:16. doi: 10.3389/fnmol.2011.00016
72. Jope, R. S., Yuskaitis, C. J., and Beurel, E. (2007). Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem. Res. 32, 577-595. doi: 10.1007/s11064-006-9128-5
73. Kaidanovich-Beilin, O., Milman, A., Weizman, A., Pick, C. G., and Eldar-Finkelman, G. (2004). Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and its effect on beta-catenin in mouse hippocampus. Biol. Psychiatry 55, 781-784. doi: 10.1016/j.biopsych.2004.01.008
74. Kang, J., Lemaire, H. G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K. H., et al. (1987). The precursor of Alzheimer's disease amyloid A4 pro-tein resembles a cell-surface receptor. Nature 325, 733-736. doi: 10.1038/ 325733a0
75. Kannan, N., and Neuwald, A. F. (2004). Evolutionary constraints associated with functional specificity of the CMGC protein kinases MAPK, CDK, GSK, SRPK, DYRK, and CK2alpha. Protein Sci. 13, 2059-2077. doi: 10.1110/ps.04637904
76. Kempermann, G., Kuhn, H. G., and Gage, F. H. (1998). Experience-induced neurogenesis in the senescent dentate gyrus. J. Neurosci. 18, 3206-3212.
77. Kessing, L. V., Forman, J. L., andAndersen, P. K. (2010). Does lithium protect against dementia? BipolarDisord. 12, 87-94. doi: 10.1111/j.1399-5618.2009.00788.x
78. Kimura, T., Yamashita, S., Nakao, S., Park, J. M., Murayama, M., Mizoroki, T., et al. I. GSK-3beta is required for memory reconsolidation in adult brain. PLoS ONE 3:e3540. doi: 10.1371/journal.pone.0003540
79. King, M. K., Pardo, M., Cheng, Y., Downey, K., Jope, R. S., and Beurel, E. (2014). Glycogen synthase kinase-3 inhibitors: rescuers of cognitive impairments. Pharmacol. Ther. 141, 1-12. doi: 10.1016/j.pharmthera.2013.07.010
80. Klein, P. S., and Melton, D. A. (1996). A molecular mechanism for the effect of lithium on development. Proc. Natl. Acad. Sci. U.S.A. 93, 8455-8459. doi: 10.1073/pnas.93.16.8455
81. Knoth, R., Singec, I., Ditter, M., Pantazis, G., Capetian, P., Meyer, R. P., et al. (2010). Murine features of neurogenesis in the human hippocampus across the lifespan from 0 to 100 years. PLoS ONE 5:e8809. doi: 10.1371/journal.pone.0008809
82. Koh, S. H., Noh, M.Y., and Kim, S. H. (2008). Amyloid-beta-induced neurotoxicity is reduced by inhibition of glycogen synthase kinase-3. Brain Res. 1188, 254-262. doi: 10.1016/j.brainres.2007.10.064
83. Koike, H., Tomioka, S., Sorimachi, H., Saido, T. C., Maruyama, K., Okuyama, A., et al. (1999). Membrane-anchoredmet alloproteaseMDC9 hasan alpha-secretase activity responsible for processing the amyloid precursor protein. Biochem. J. 343(Pt 2), 371-375. doi: 10.1042/0264-6021:3430371
84. Kokubo, H., Kayed, R., Glabe, C. G., and Yamaguchi, H. (2005). Soluble Abeta oligomers ultrastructurally localize to cell processes and might be related to synaptic dysfunction in Alzheimer's disease brain. Brain Res. 1031, 222-228. doi: 10.1016/j.brainres.2004.10.041
85. Leclerc, S., Garnier, M., Hoessel, R., Marko, D., Bibb, J. A., Snyder, G. L., et al. (2001). Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? J. Biol. Chem. 276, 251-260. doi: 10.1074/jbc.M002466200
86. Leost, M., Schultz, C., Link, A.,Wu Y. Z., Biernat, J., Mandelkow, E. M., et al. (2000). Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25. Eur. J. Biochem. 267, 5983-5994. doi: 10.1046/j.1432-1327.2000.01673.x
87. Leroy, K., Yilmaz, Z., and Brion, J. P. (2007). Increased level of active GSK-3beta in Alzheimer's disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration. Neuropathol. Appl. Neurobiol. 33, 43-55. doi: 10.1111/j.1365-2990.2006.00795.x
88. Leyhe, T., Eschweiler, G. W., Stransky, E., Gasser, T., Annas, P., Basun, H., et al. J. Increase of BDNF serum concentration in lithium treated patients with earlyAlzheimer's disease. J. AlzheimersDis. 16, 649-656. doi: 10.3233/JAD-2009-1004
89. Li, T., Hawkes, C., Qureshi, H. Y., Kar, S., and Paudel, H. K. (2006). Cyclin-dependent protein kinase 5 primes microtubule-associated protein tau site-specifically for glycogen synthase kinase 3beta. Biochemistry 45, 3134-3145. doi: 10.1021/bi051635j
90. Li, T., and Paudel, H. K. (2006). Glycogen synthase kinase 3beta phosphorylates Alzheimer's disease-specific Ser396 of microtubule-associated protein tau by a sequential mechanism. Biochemistry 45, 3125-3133. doi: 10.1021/bi051634r
91. Liao, D., Hessler, N.A., and Malinow, R. (1995).Activation of postsynapticallysilent synapses during pairing-induced LTP in CA1 region of hippocampal slice. Nature 375, 400-404. doi: 10.1038/375400a0
92. Liu, X. S., Xue, Q. S., Zeng, Q. W., Li, Q., Liu, J., Feng, X. M., et al. (2010). Sevoflurane impairs memory consolidation in rats, possibly through inhibiting phosphory-lation of glycogen synthase kinase-3beta in the hippocampus. Neurobiol. Learn. Mem. 94, 461-467. doi: 10.1016/j.nlm.2010.08.011
93. Llorens-Martin, M., Fuster-Matanzo, A., Teixeira, C. M., Jurado-Arjona, J., Ulloa, F., et al. (2013). GSK-3beta overexpression causes reversible alterations on post-synaptic densities and dendritic morphology of hippocampal granule neurons in vivo. Mol. Psychiatry 18, 451-460. doi: 10.1038/mp.2013.4
94. Llorens-Martin, M., Lopez-Domenech, G., Soriano, E., and Avila, J. (2011). GSK3beta is involved in the relief of mitochondria pausing in a tau-dependent manner. PLoS ONE 6:e27686. doi: 10.1371/journal.pone.0027686
95. Loberg, R. D., Vesely, E., and Brosius, F. C. III. (2002). Enhanced glycogen synthase kinase-3beta activity mediates hypoxia-induced apoptosis of vascular smooth muscle cells andis preventedbyglucose transportand metabolism. J. Biol. Chem. 4 41667-41673. doi: 10.1074/jbc.M206405200
96. Lovestone, S., Hartley, C. L., Pearce, J., andAnderton, B. H. (1996). Phosphorylation of tau by glycogen synthase kinase-3 beta in intact mammalian cells: the effects on the organization and stability of microtubules. Neuroscience 73, 1145-1157. doi: 10.1016/0306-4522(96)00126-1
97. Lucas, J. J., Hernandez, F., Gomez-Ramos, P., Moran, M. A., Hen, R., and Avila, J. (2001). Decreasednuclear beta-catenin, tau hyperphosphorylation and neurode-generation in GSK-3beta conditional transgenic mice. EMBO J. 20, 27-39. doi: 10.1093/emboj/20.1.27
98. Luna-Munoz, J., Chavez-Macias, L., Garcia-Sierra, F., and Mena, R. (2007). Earliest stages of tau conformational changes are related to the appearance of a sequence of specific phospho-dependent tau epitopes in Alzheimer's disease. J. Alzheimers Dis. 12, 365-375.
99. Luo, Y., Bolon, B., Kahn, S., Bennett, B. D., Babu-Khan, S., Denis, P., et al. (2001). Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal pheno-type and abolished beta-amyloid generation. Nat. Neurosci. 4, 231-232. doi: 10.1038/85059
100. Luthi, A., Chittajallu, R., Duprat, F., Palmer, M. J., Benke, T. A., Kidd, F. L., et al. (1999). Hippocampal LTD expression involves a pool of AMPARs regulated by the NSF-GluR2 interaction. Neuron 24, 389-399. doi: 10.1016/S0896-6273(00)80852-1
101. Ly, P. T., Wu, Y., Zou, H., Wang, R., Zhou, W., Kinoshita, A., et al. (2013). Inhi-bition of GSK3beta-mediated BACE1 expression reduces Alzheimer-associated phenotypes. J. Clin. Invest. 123, 224-235. doi: 10.1172/JCI64516
102. Macdonald, A., Briggs, K., Poppe, M., Higgins, A., Velayudhan, L., and Lovestone, S. K. A feasibility and tolerability study of lithium in Alzheimer's disease. Int. J. Geriatr. Psychiatry 23, 704-711. doi: 10.1002/gps.1964
103. Magdesian, M. H., Carvalho, M. M., Mendes, F. A., Saraiva, L. M., Juliano, M. A., Juliano, L. J., et al. (2008). Amyloid-beta binds to the extracellular cysteine-rich domain of Frizzled and inhibits Wnt/beta-catenin signaling. J. Biol. Chem. 283, 9359-9368. doi: 10.1074/jbc.M707108200
104. Manahan-Vaughan, D. (2010). MicroRNAs contribute to LTP in the hippocampus in vivo (Commentary on Wibrand et al.). Eur. J. Neurosci. 31, 634-635. doi: 10.1111/j.1460-9568.2010.07140.x
105. Martin, M., Rehani, K., Jope, R. S., and Michalek, S. M. (2005). Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat. Immunol. 6, 777-784. doi: 10.1038/ni1221
106. Martinez, A., Alonso, M., Castro, A., Perez, C., and Moreno, F. J. (2002). First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J. Med. Chem. 45, 1292-1299. doi: 10.1021/jm011020u
107. Martinez, A., Gil, C., and Perez, D. I. (2011). Glycogen synthase kinase 3 inhibitors in the next horizon forAlzheimer's disease treatment. Int. J. AlzheimersDis. 2011, 280502. doi: 10.4061/2011/280502
108. Montenegro-Venegas, C., Tortosa, E., Rosso, S., Peretti, D., Bollati, F., Bisbal, M., et al. (2010). MAP1B regulates axonal development by modulating Rho-GTPase Rac1 activity. Mol. Biol. Cell 21, 3518-3528. doi: 10.1091/mbc.E09-08-0709
109. Nagy, Z., Esiri, M. M., Cato, A. M., and Smith, A. D. (1997a). Cell cycle markers in the hippocampus in Alzheimer's disease. Acta Neuropathol. 94, 6-15. doi: 10.1007/s004010050665
110. Nagy, Z., Esiri, M. M., and Smith, A. D. (1997b). Expression of cell division markers in the hippocampus in Alzheimer's disease and other neurodegenerative conditions. Acta Neuropathol. 93, 294-300. doi: 10.1007/s004010050617
111. Nunes, P. V., Forlenza, O. V., and Gattaz, W. F. (2007). Lithium and risk for Alzheimer's disease in elderly patients with bipolar disorder. Br. J. Psychiatry 190, 359-360. doi: 10.1192/bjp.bp.106.029868
112. Palomo, V., Soteras, I., Perez, D. I., Perez, C., Gil, C., Campillo, N. E., et al. (2011). Exploring the binding sites of glycogen synthase kinase 3. Identification and characterization of allosteric modulation cavities. J. Med. Chem. 54, 8461-8470. doi: 10.1021/jm200996g
113. Pap, M., and Cooper, G. M. (1998). Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-kinase/Akti cell survival pathway. J. Biol. Chem. 273, 19929-19932. doi: 10.1074/jbc.273.32.19929
114. Pap, M., and Cooper, G. M. (2002). Role oftranslationinitiation factor 2Bincontrol of cell survival bythe phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3betasignalingpathway. Mol. Cell. Biol. 22, 578-586. doi: 10.1128/MCB.22.2.578-586.2002
115. Peineau, S., Taghibiglou, C., Bradley, C., Wong, T. P., Liu, L. Lu, J., et al. (2007). LTP inhibits LTD in the hippocampus via regulation of GSK3beta. Neuron 53, 703-717. doi: 10.1016/j.neuron.2007.01.029
116. Phiel, C. J., Wilson, C. A., Lee, V. M., and Klein, P. S. (2003). GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 423, 435-439. doi: 10.1038/nature01640
117. Pigino, G., G. Morfini, Pelsman, A., Mattson, M. P., Brady, S. T., and Busciglio, J. (2003). Alzheimer's presenilin 1 mutations impair kinesin-based axonal transport. J. Neurosci. 23, 4499-4508.
118. Plattner, F., Angelo, M., and Giese, K. P. (2006). The roles of cyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation. J. Biol. Chem. 281, 25457-25465. doi: 10.1074/jbc.M603469200
119. Plotkin, B., Kaidanovich, O., Talior, I., and Eldar-Finkelman, H. (2003). Insulin mimetic action of synthetic phosphorylated peptide inhibitors of glycogen synthase kinase-3. J. Pharmacol. Exp. Ther. 305, 974-980. doi: 10.1124/jpet.102.047381
120. Plotkin, D. A., and Jarvik, L. F. (1986). Cholinergic dysfunction in Alzheimer dis-ease: cause or effect? Prog. Brain Res. 65, 91-103. doi: 10.1016/S0079-6123(08) 60644-5
121. Pomara, N. (2009). Lithium treatment in Alzheimer's disease does not pro-mote cognitive enhancement, but may exert long-term neuroprotective effects. Psychopharmacology(Berl.)205, 169-170. doi: 10.1007/s00213-009-1510-y
122. Pope, W., Enam, S. A., Bawa, N., Miller, B. E., Ghanbari, H. A., and Klein, W. L. (1993). Phosphorylated tau epitope of Alzheimer's disease is coupled to axon development in the avian central nervous system. Exp. Neurol. 120, 106-113. doi: 10.1006/exnr.1993.1044
123. Rabacchi, S. A., Bailly, Y., Delhaye-Bouchaud, N., Herrup, K., and Mariani, J. (1992). Role of the target in synapse elimination: studies in cerebellum of developing lurcher mutants and adult chimeric mice. J. Neurosci. 12, 4712-4720.
124. Rapoport, M., Dawson, H. N., Binder, L. I., Vitek, M. P., and Ferreira, A. (2002). Tau is essential to beta-amyloid-induced neurotoxicity. Proc. Natl. Acad. Sci. U.S.A. 99, 6364-6369. doi: 10.1073/pnas.092136199
125. Rauk, A. (2008).Whyis the amyloid betapeptide ofAlzheimer's disease neurotoxic? Dalton Trans. 1273-1282. doi: 10.1039/b718601k
126. Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., et al. (2007). Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 316, 750-754. doi: 10.1126/science.1141736
127. Robert, M., and Mathuranath, P. S. (2007). Tau and tauopathies. Neurol. India 55, 11-16. doi: 10.4103/0028-3886.30420
128. Rockenstein, E., Crews, L., and Masliah, E. (2007a). Transgenic animal models of neurodegenerative diseases and their application to treatment development. Adv. DrugDeliv. Rev. 59, 1093-1102. doi: 10.1016/j.addr.2007.08.013
129. Rockenstein, E., Torrance, M., Adame, A., Mante, M., Bar-On, P., Rose, J. B., et al. (2007b). Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation. J. Neurosci. 27, 1981-1991. doi: 10.1523/JNEUROSCI.4321-06.2007
130. Ryan, K. A., and Pimplikar, S. W. (2005). Activation of GSK-3 and phosphorylation of CRMP2 in transgenic mice expressing APP intracellular domain. J. Cell Biol. 171, 327-335. doi: 10.1083/jcb.200505078
131. Saeki, K., Machida, M., Kinoshita, Y., Takasawa, R., and Tanuma, S. (2011). Glycogen synthase kinase-3beta2 has lower phosphorylation activity to tau than glycogen synthase kinase-3beta1. Biol. Pharm. Bull. 34, 146-149. doi: 10.1248/bpb.34.146
132. Saito, Y., Vandenheede, J. R., and Cohen, P. (1994). The mechanism by which epi-dermal growth factor inhibits glycogen synthase kinase 3 in A431 cells. Biochem. J. 303(Pt 1), 27-31.
133. Samadi, A., Valderas, C., de los Rios, C., Bastida, A., Chioua, M., Gonzalez-Lafuente, L., et al. (2011). Cholinergic and neuroprotective drugs for the treatment of Alzheimer and neuronal vascular diseases. II. Synthesis, biologi-cal assessment, and molecular modelling of new tacrine analogues from highly substituted 2-aminopyridine-3-carbonitriles. Bioorg. Med. Chem. 19, 122-133. doi: 10.1016/j.bmc.2010.11.040
134. Sanchez, C., Perez, M., and Avila, J. (2000). GSK3beta-mediated phosphorylation of the microtubule-associated protein 2C (MAP2C) prevents microtubule bundling. Eur. J. Cell Biol. 79, 252-260. doi: 10.1078/S0171-9335(04)70028-X
135. Santacruz, K., Lewis, J., Spires, T., Paulson, J., Kotilinek, L., Ingelsson, M., et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science 309, 476-481. doi: 10.1126/science.1113694
136. Sengupta, A., Kabat, J., Novak, M., Wu, Q., Grundke-Iqbal, I., and Iqbal, K. (1998). Phosphorylation of tau at both Thr 231 and Ser 262 is required for maximal inhibition of its binding to microtubules. Arch. Biochem. Biophys. 357, 299-309. doi: 10.1006/abbi.1998.0813
137. Sengupta, A., Novak, M., Grundke-Iqbal, I., and Iqbal, K. (2006). Regu-lation of phosphorylation of tau by cyclin-dependent kinase 5 and glyco-gen synthase kinase-3 at substrate level. FEBS Lett. 580, 5925-5933. doi: 10.1016/j.febslet.2006.09.060
138. Sereno, L., Coma, M., Rodriguez, M., Sanchez-Ferrer, P., Sanchez, M. B., Gich, L., et al. (2009). A novel GSK-3beta inhibitor reduces Alzheimer's pathol-ogy and rescues neuronal loss in vivo. Neurobiol. Dis. 35, 359-367. doi: 10.1016/j.nbd.2009.05.025
139. Sergeant, N., Bretteville, A., Hamdane, M., Caillet-Boudin, M. L., Grognet, P., Bombois, S., et al. (2008). Biochemistry of tau in Alzheimer's disease and related neurological disorders. Expert Rev. Proteomics 5, 207-224. doi: 10.1586/14789450.5.2.207
140. Shipton, O. A., Leitz, J. R., Dworzak, J., Acton, C. E., Tunbridge, E. M., Denk, F., et al. (2011). Tau protein is required for amyloid {beta}-induced impair-ment of hippocampal long-term potentiation. J. Neurosci. 31, 1688-1692. doi: 10.1523/JNEUROSCI.2610-10.2011
141. Sirerol-Piquer, M., Gomez-Ramos, P., Hernandez, F., Perez, M., Moran, M. A., Fuster-Matanzo, A., et al. (2011). GSK3beta overexpression induces neuronal death and a depletion of the neurogenic niches in the dentate gyrus. Hippocampus 21, 910-922.
142. Soutar, M. P., Kim, W. Y., Williamson, R., Peggie, M., Hastie, C. J., McLauch-lan, H., et al. (2010). Evidence that glycogen synthase kinase-3 isoforms have distinct substrate preference in the brain. J. Neurochem. 115, 974-983. doi: 10.1111/j.1471-4159.2010.06988.x
143. Spittaels, K., Van den Haute, C., Van Dorpe, J., Terwel, D., Vandezande, K., Lasrado, R., et al. (2002). Neonatal neuronal overexpression of glycogen synthase kinase-C. beta reduces brain size in transgenic mice. Neuroscience 113, 797-808. doi: 10.1016/S0306-4522(02)00236-1
144. Sudduth, T. L., Schmitt, F. A., Nelson, P. T., and Wilcock, D. M. (2013). Neuroinflam-matory phenotype in early Alzheimer's disease. Neurobiol. Aging 34, 1051-1059. doi: 10.1016/j.neurobiolaging.2012.09.012
145. Sudduth, T. L., Wilson, J. G., Everhart, A., Colton, C. A., and Wilcock, D. M. (2012). Lithium treatment of APPSwDI/NOS2-/-mice leads to reduced hyperphosphorylated tau, increased amyloid deposition and altered inflammatory phenotype. PLoS ONE 7:e31993. doi: 10.1371/journal.pone. 0031993
146. Sun, W., Qureshi, H. Y., Cafferty, P. W., Sobue, K., Agarwal-Mawal, A., et al. (2002). Glycogen synthase kinase-3beta is complexed with tau protein in brain microtubules. J. Biol. Chem. 277, 11933-11940. doi: 10.1074/jbc. M107182200
147. Sutherland, C., and Cohen, P. (1994). The alpha-isoform of glycogen syn-thase kinase-3 from rabbit skelet al muscle is inactivated by p70 S6 kinase or MAP kinase-activated protein kinase-1 in vitro. FEBS Lett. 338, 37-42. doi: 10.1016/0014-5793(94)80112-6
148. Sutherland, C., Leighton, I. A., and Cohen, P. (1993). Inactivation of glycogen synthase kinase-3 beta by phosphorylation: new kinase connections in insulin and growth-factor signalling. Biochem. J. 296(Pt 1), 15-19.
149. Takashima, A., Noguchi, K., Michel, G., Mercken, M., Hoshi, M., Ishiguro, K., et al. (1996a). Exposure of rat hippocampal neurons to amyloid beta peptide (25-35) induces the inactivation of phosphatidyl inositol-3 kinase and the activation of tau protein kinase I/glycogen syn-thase kinase-3 beta. Neurosci. Lett. 203, 33-36. doi: 10.1016/0304-3940(95) 12257-5
150. Takashima, A., Sato, M., Mercken, M., Tanaka, S., Kondo, S., Honda, T., et al. (1996b). Localization of Alzheimer-associated presenilin 1 in transfected COS-7 cells. Biochem. Biophys. Res. Commun. 227, 423-426. doi: 10.1006/bbrc.1996.1523
151. Terwel, D., Muyllaert, D., Dewachter, I., Borghgraef, P., Croes, S., Devijver, H., et al. (2008). Amyloid activates GSK-3beta to aggravate neuronal tauopa-thy in bigenic mice. Am. J. Pathol. 172, 786-798. doi: 10.2353/ajpath.2008. 070904
152. Thotala, D. K., Hallahan, D. E., and Yazlovitskaya, E. M. (2008). Inhibition of glyco-gen synthase kinase 3 beta attenuates neurocognitive dysfunction resulting from cranial irradiation. CancerRes. 68, 5859-5868. doi: 10.1158/0008-5472.CAN-07-6327
153. Toledo, E. M., and Inestrosa, N. C. (2010). Activation of Wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neuro degeneration in brains of an APPswe/PSEN1DeltaE9 mouse model of Alzheimer's disease. Mol. Psychiatry 15, 272-285, 228. doi: 10.1038/mp.2009.72
154. Townsend, M., Mehta, T., and Selkoe, D. J. (2007). Soluble Abeta inhibits specific signal transduction cascades common to the insulin receptor pathway. J. Biol. Chem. 282, 33305-33312. doi: 10.1074/jbc.M610390200
155. Uemura, K., Kuzuya, A., Shimozono, Y., Aoyagi, N., Ando, K., Shimohama, S., et al. (2007). GSK3beta activity modifies the localization and function of presenilin 1. J. Biol. Chem. 282, 15823-15832. doi: 10.1074/jbc.M610708200
156. Van Hoesen, G. W., Hyman, B. T., and Damasio, A. R. (1991). Entorhi-nal cortex pathology in Alzheimer's disease. Hippocampus 1, 1-8. doi: 10.1002/hipo.450010102
157. Wang, H., Wang, R., Zhao, Z., Ji, Z., Xu, S., Holscher, C., et al. (2009). Coexistences of insulin signaling-related proteins and choline acetyltransferase in neurons. Brain Res. 1249, 237-243.doi:10.1016/j.brainres.2008.10.046
158. Wang, Y., Ju, W., Liu, L., Fam, S., D'Souza, S., Taghibiglou, C., et al. (2004). alpha-Amino-3-hydroxy-5-methylisoxazole-4-propionic acid subtype glutamate receptor (AMPAR) endocytosis is essential for N-methyl-D-aspartate-induced neuronal apoptosis. J. Biol. Chem. 279, 41267-41270. doi: 10.1074/jbc. C400199200
159. Watcharasit, P., Bijur, G. N., Song, L., Zhu, J., Chen, X., and Jope, R. S. (2003). Glycogen synthase kinase-3beta (GSK3beta) binds to and promotes the actions of p53. J. Biol. Chem. 278, 48872-48879. doi: 10.1074/jbc. M305870200
160. Wei, J., Liu, W., and Yan, Z. (2010). Regulation of AMPA receptor trafficking and function by glycogen synthase kinase 3. J. Biol. Chem. 285, 26369-26376. doi: 10.1074/jbc.M110.121376
161. Welsh, G. I., and Proud, C. G. (1993). Glycogen synthase kinase-3 is rapidly inac-tivated in response to insulin and phosphorylates eukaryotic initiation factor eIF-2B. Biochem. J. 294(Pt 3), 625-629.
162. Whitehouse, P. J., Price, D. L., Clark, A. W., Coyle, J. T., and DeLong, M. R. (1981). Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann. Neurol. 10, 122-126. doi: 10.1002/ana.410100203
163. Witton, J., Brown, J. T., Jones, M. W., and Randall, A. D. (2010). Altered synap-tic plasticity in the mossy fibre pathway of transgenic mice expressing mutant amyloid precursor protein. Mol. Brain 3, 32. doi: 10.1186/1756-6606-3-32
164. Wu, G., and He, X. (2006). Threonine 41 in beta-catenin serves as a key phospho-rylation relay residue in beta-catenin degradation. Biochemistry 45, 5319-5323. doi: 10.1021/bi0601149
165. Yates, C. M., Simpson, J., Gordon, A., Maloney, A. F., Allison, Y., Ritchie, I. M., et al. (1983). Catecholamines and cholinergic enzymes in pre-senile and senile Alzheimer-type dementia and Down's syndrome. Brain Res. 280, 119-126. doi: 10.1016/0006-8993(83)91179-4
166. Zhang, H., Ma, Q., Zhang, Y. W., and Xu, H. (2012). Proteolytic processing of Alzheimer's beta-amyloid precursor protein. J. Neurochem. 120(Suppl. 1), 9-21. doi: 10.1111/j.1471-4159.2011.07519.x
167. Zhang, W., Zhao, Y., Tong, C., Wang, G., Wang, B., Jia, J., et al. (2005). Hedgehog-regulated Costal2-kinase complexes control phosphorylation and proteolytic processing of Cubitus interruptus. Dev. Cell 8, 267-278. doi: 10.1016/j.devcel.2005.01.001
168. Zhao, C., Teng, E. M., Summers, R. G., Ming, G. L. Jr., and Gage, F. H. (2006). Dis-tinct morphological stages of dentate granule neuron maturation in the adult mouse hippocampus. J. Neurosci. 26, 3-11. doi: 10.1523/JNEUR0SCI.3648-05.2006
169. Zumbrunn, J., Kinoshita, K., Hyman, A. A., and Nathke, I. S. (2001). Binding of the adenomatous polyposis coli protein to microtubules increases microtubule stability and is regulated by GSK3 beta phosphorylation. Curr. Biol. 11, 44-49. doi: 10.1016/S0960-9822(01)00002-1